Relay Therapeutics — Third Quarter 2026 Earnings Summary

Relay Therapeutics reported third-quarter 2026 financial results showing a net loss of $81.7 million and ending the period with $848.6 million in cash, cash equivalents, and investments. The company's Phase 3 ReDiscover-2 trial for zovegalisib in second-line breast cancer is on track to complete enrollment by mid-2027, while updated data from the ReInspire trial for vascular anomalies will be presented at the ASH Annual Meeting in December 2026. Relay announced the appointment of Shannon Campbell as Head of Commercial to lead preparations for the commercialization of zovegalisib and revealed a new late-stage preclinical program for a mutant-selective TIE2 inhibitor. Additionally, the FDA granted full approval for LYRFIGTU (lirafugratinib), the first medicine to emerge from Relay's Dynamo platform, for the treatment of cholangiocarcinoma.